CalciMedica is developing oral CRAC channel inhibitors for chronic indications treated in an outpatient setting. Several highly selective candidates with attractive pharmacokinetic properties that are consistent with once-daily oral dosing are currently in pre-clinical toxicology testing and in confirmatory studies in several animal models including chronic pancreatitis.